Bezinga has around 25 million readers per month including 45 million monthly views. Their reach also includes 240,000 brokerage partners and more than 700 large institutional investors.
A well done informational piece on RDGL will have a positive impact in getting exposure to those investors and educate them on the success of IsoPet and RadioGel has in killing cancer.
This company has always struggled in getting enough people to actually understand just how game changing their treatment is— hopefully the Bezinga article will drum up more interest.
Regardless, the FDA BDD designation and likely IDE approval confirm what all of us have know for a long time— this is a diamond in the rough company that will change the face of cancer treatment soon!
Share price will be up significantly in the next 12-24 months
News 
Market Data 
Discover 
AI
